-
The American Journal of Medicine Jul 1988
Topics: Aged; Antibodies, Antinuclear; Female; Humans; Hypertension; Methyldopa; Thrombocytopenia
PubMed: 3260451
DOI: 10.1016/0002-9343(88)90518-9 -
The Journal of Clinical Psychiatry Nov 1978The dopamine hypothesis of schizophrenia suggests that there is a functional excess of dopaminergic activity within the brain of schizophrenics. Alpha-methyldopa...
The dopamine hypothesis of schizophrenia suggests that there is a functional excess of dopaminergic activity within the brain of schizophrenics. Alpha-methyldopa interferes with dopaminergic transmission in the central nervous system. We report a case of a schizophrenic in whom, after an overdose of alpha-methyldopa, there was a dramatic and apparently complete resolution of psychotic symptomatology, followed after a few weeks by a sudden return of psychosis.
Topics: Adult; Humans; Male; Methyldopa; Recurrence; Schizophrenia; Suicide, Attempted
PubMed: 721785
DOI: No ID Found -
Archives of Dermatology Mar 1988
Topics: Aged; Female; Humans; Methyldopa; Photosensitivity Disorders
PubMed: 3345083
DOI: 10.1001/archderm.124.3.326 -
British Journal of Pharmacology Oct 1971
Topics: Animals; Bile; Brain; Carbon Dioxide; Carbon Isotopes; Feces; Liver; Methylation; Methyldopa; Oxidation-Reduction; Rats
PubMed: 5158231
DOI: No ID Found -
The Medical Journal of Australia Jul 1967
Topics: Anemia, Hemolytic; Coombs Test; Humans; Hypertension; Methyldopa
PubMed: 6031263
DOI: 10.5694/j.1326-5377.1966.tb72744.x -
Clinical Pharmacology and Therapeutics Apr 1985To assess the problem of alpha-methyldopa dosing in lactating mothers with hypertension, we studied three breast-feeding women to determine simultaneous plasma and...
To assess the problem of alpha-methyldopa dosing in lactating mothers with hypertension, we studied three breast-feeding women to determine simultaneous plasma and breast milk concentrations of alpha-methyldopa after a 500 mg oral dose while receiving continuous therapy. Peak excretion of free alpha-methyldopa in breast milk ranged from 0.02 to 1.14 microgram/ml. The breast milk/whole plasma ratios of alpha-methyldopa ranged from 0.19 to 0.34. In two of the three breast-fed infants, plasma levels of alpha-methyldopa were undetectable (less than 0.05 microgram/ml) 6 hours after maternal ingestion of the drug, but in one of these the plasma alpha-methyldopa concentration was 0.09 microgram/ml 10 hours after maternal dosing. It is estimated that when the mother receives 1 gm alpha-methyldopa a day, the maximal cumulative dose of alpha-methyldopa would be 855 micrograms and the average cumulative alpha-methyldopa load to the breast-fed infant would be 195 micrograms, or 0.02% of the maternal dose.
Topics: Administration, Oral; Adult; Animals; Chromatography, High Pressure Liquid; Female; Humans; Hydrogen-Ion Concentration; Hypertension; Infant, Newborn; Kinetics; Lactation; Methyldopa; Milk; Pregnancy
PubMed: 3838502
DOI: 10.1038/clpt.1985.59 -
Lancet (London, England) Jan 1966
Topics: Anemia, Hemolytic; Humans; Methyldopa
PubMed: 4159083
DOI: 10.1016/s0140-6736(66)90078-x -
Journal of Pharmacokinetics and... Aug 1985alpha-Methyldopa was intraarterially and orally administered to dogs at two dose levels in a randomized complete crossover design. The appearance of secondary peaks in...
alpha-Methyldopa was intraarterially and orally administered to dogs at two dose levels in a randomized complete crossover design. The appearance of secondary peaks in the plasma concentration-time profiles indicated the presence of enterohepatically recycled methyldopa. This was established by the absence of a secondary peak following readministration of a dose after biliary cannulation and the detection of methyldopa in the bile of a cannulated dog. Enterohepatic recirculation was estimated to account for a mean of 16.2% of the area under the plasma concentration-time profile after intraarterial administration. Total systemic clearance, defined as the sum of elimination by all routes from the general circulation of the administered dose, and corrected for enterohepatic recirculation, averaged (+/- SD) 99.4 +/- 24.6 ml/min in the dog. An extended average apparent terminal half-life of 6.0 +/- 5.2 hr was exhibited after oral administration compared to an average half-life of 3.1 +/- 1.8 hr following intraarterial administration. Elimination kinetics were linear in the dose range studied. Oral plasma concentration data suggest that the apparent bioavailable fraction may be dose dependent.
Topics: Administration, Oral; Animals; Bile; Dogs; Half-Life; Injections, Intra-Arterial; Kinetics; Male; Methyldopa; Models, Biological; Software
PubMed: 3841366
DOI: 10.1007/BF01061477 -
Journal of the Indian Medical... Jun 1968
Topics: Adolescent; Adult; Aged; Female; Humans; Hypertension; Male; Methyldopa; Middle Aged
PubMed: 5708637
DOI: No ID Found -
European Journal of Clinical... 1995Methyldopa urine and plasma levels and urine metabolite levels were assessed following intravenous (IV) and oral (PO) methyldopa before, and after ingestion of...
Methyldopa urine and plasma levels and urine metabolite levels were assessed following intravenous (IV) and oral (PO) methyldopa before, and after ingestion of methyldopa (500 mg) daily for eight weeks. There was no increase in (estimated) methyldopa absorption (8.4%) or renal clearance (PO 13.9%, IV 2.33%) after the eight weeks of methyldopa ingestion. However, the initial methyldopa absorption and renal clearance values in this study were higher than that in previous studies. There was an inverse relation between the initial methyldopa absorption and the change in absorption (r - 0.605) and between the initial methyldopa renal clearance and the change in renal clearance (PO r -0.874, IV r -0.891). Overall, this study did not confirm our previous studies showing induction of methyldopa absorption and renal clearance, possibly due to prior up regulation of transporter function. Consistent with methyldopa inducing drug transporters, those with low initial absorption and renal clearance values had the greatest increases.
Topics: Absorption; Administration, Oral; Adult; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Kidney; Male; Methyldopa
PubMed: 8641329
DOI: 10.1007/BF00194957